NWI Management LP Takes Position in Becton, Dickinson and Company $BDX

by · The Markets Daily

NWI Management LP bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) during the first quarter, HoldingsChannel reports. The fund bought 225,000 shares of the medical instruments supplier’s stock, valued at approximately $35,377,000. Becton, Dickinson and Company comprises about 2.0% of NWI Management LP’s investment portfolio, making the stock its 13th biggest holding.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC raised its holdings in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the last quarter. Empowered Funds LLC grew its holdings in shares of Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after buying an additional 1,354 shares during the last quarter. United Bank increased its position in Becton, Dickinson and Company by 23.9% in the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock valued at $887,000 after acquiring an additional 993 shares during the period. Marshall Wace LLP raised its stake in Becton, Dickinson and Company by 365.1% during the 2nd quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock valued at $5,491,000 after acquiring an additional 25,022 shares during the last quarter. Finally, NewEdge Advisors LLC raised its stake in Becton, Dickinson and Company by 34.7% during the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock valued at $4,048,000 after acquiring an additional 6,058 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,189 shares of company stock valued at $765,661 in the last quarter. Insiders own 0.40% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the topic of several analyst reports. The Goldman Sachs Group lowered their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Weiss Ratings cut Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. UBS Group assumed coverage on Becton, Dickinson and Company in a report on Tuesday. They set a “buy” rating and a $190.00 price target for the company. Piper Sandler lowered their price objective on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Finally, Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a research note on Tuesday, April 14th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $180.93.

Check Out Our Latest Report on Becton, Dickinson and Company

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $166.19 on Friday. The stock has a market capitalization of $45.79 billion, a price-to-earnings ratio of 42.07, a PEG ratio of 11.80 and a beta of 0.21. The business’s 50 day moving average is $151.85 and its two-hundred day moving average is $163.64. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. During the same period in the previous year, the business earned $3.35 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Research analysts expect that Becton, Dickinson and Company will post 12.53 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.5%. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Further Reading

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).